Furmecil Capsule

Furmecil capsule is an anticancer medicine with combination of gimeracil, oteracil, and tegafur. It prescribes to treat stomach cancer alone or in combination with some medicines as part of combination chemotherapy. It works by interfering with the pathways that promote growth of cancer cells and eventually destroying them. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

• Stomach cancer

Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately.

Some common side effects of Furmecil Capsule include:

• Bone marrow suppression
• Acute renal failure
• Diarrhea
• Dehydration
• Electrolyte imbalance
• Lacrimation (flow of tears)

Contact your doctor immediately if you experience any severe or unusual side effects.

• The dosage of Furmecil Capsule is determined by the doctor based on your health condition.
• This medication should be taken orally on an empty stomach, or it can be consumed one hour before a meal or two hours after a meal. In the event of an overdose, contact your doctor immediately.
  
  

• Furmecil Capsule is a combination anticancer medicine with gimeracil, oteracil, and tegafur. In which tegafur gets converted into 5-fluorouracil (a chemical) that interferes with the synthesis of genetic materials (RNA and DNA) in the cancer cells and slows down the progression of cancer.
• Gimeracil prevents the breakdown of 5-FU, that helps to maintain high concentrations of 5-FU against cancer cells and Oteracil suppresses 5-FU’s gastrointestinal toxicity.

• Kobayakawa, M., & Kojima, Y. (2011). Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoTargets and therapy, 193-201.
• Zhang, X., Tian, X., Wei, Y., Deng, H., Ma, L., & Chen, Z. (2021). Activity and Safety of Tegafur, Gimeracil, and Oteracil Potassium for Nasopharyngeal Carcinoma: A Systematic Review and Meta‐Analysis. Journal of Oncology, 2021(1), 6690275.
• Kinoshita, T., Nashimoto, A., Yamamura, Y., Okamura, T., Sasako, M., Sakamoto, J. ... & Nakajima, T. (2004). Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer. Gastric Cancer, 7(2), 104-109.
• Matt, P., van Zwieten‐Boot, B., Calvo Rojas, G., Ter Hofstede, H., Garcia‐Carbonero, R., Camarero, J., ... & Pignatti, F. (2011). The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). The Oncologist, 16(10), 1451-1457.
• Kobayakawa, M., & Kojima, Y. (2011). Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies. OncoTargets and therapy, 193-201.